Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone
Clinical trial NCT04232761 · COMPLETED
Trial details
- NCT number
- NCT04232761
- Sponsor
- Bayer
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2020-07-07
- Primary completion
- 2024-04-29
- Enrollment
- 194
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.